USPTO Art Unit 1693 Prosecution Statistics

Art Unit Information

Art Unit: 1693
Group: 1690
Tech Center: 1600
Total Cases: 1,740
Last Active: February 2025

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19061509HYDROXYPROPYL BETA-CYCLODEXTRIN COMPOSITIONS AND METHODSFebruary 2025May 2025Allow200YesNo
19061577HYDROXYPROPYL BETA-CYCLODEXTRIN COMPOSITIONS AND METHODSFebruary 2025May 2025Allow300YesNo
19031698NICOTINAMIDE RIBOSIDE HYDROGEN MALATE CRYSTAL, AND ITS PREPARATION METHOD AND APPLICATIONJanuary 2025April 2025Allow300NoNo
19028631HYDROXYPROPYL BETA-CYCLODEXTRIN COMPOSITIONS AND METHODSJanuary 2025May 2025Allow410YesNo
19002103POSITIVE MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4December 2024June 2025Allow610NoNo
18963281METHOD OF MAKING NICOTINAMIDE RIBOFURANOSIDE SALTS, NICOTINAMIDE RIBOFURANOSIDE SALTS AS SUCH, AND USES THEREOFNovember 2024April 2025Allow510NoNo
18889398METHODS AND KITS USEFUL FOR DIAGNOSIS OF HUMAN PAPILLOMAVIRUS (HPV)September 2024February 2025Allow420NoNo
18885065GLP-1R Agonist and Therapeutic Method ThereofSeptember 2024December 2024Allow300YesNo
18828652MARIBAVIR ISOMERS, COMPOSITIONS, METHODS OF MAKING AND METHODS OF USINGSeptember 2024April 2025Allow720NoNo
18813024BETA-GLUCAN-RICH LENTINULA EDODES POLYSACCHARIDE AND PREPARATION METHOD THEREOFAugust 2024November 2024Allow200NoNo
18792393ARNATAR COMPOUNDS AND METHODS FOR ENHANCED CELLULAR UPTAKEAugust 2024October 2024Allow300NoNo
18792077COLON-TARGETED ACTIVE AGENT DELIVERY CARRIER AND USES THEREOFAugust 2024June 2025Allow1030YesNo
18777489VIRAL INHIBITORS, THE SYNTHESIS THEREOF, AND INTERMEDIATES THERETOJuly 2024April 2025Allow820NoNo
18777473VIRAL INHIBITORS, THE SYNTHESIS THEREOF, AND INTERMEDIATES THERETOJuly 2024January 2025Allow610NoNo
18777501VIRAL INHIBITORS, THE SYNTHESIS THEREOF, AND INTERMEDIATES THERETOJuly 2024January 2025Allow610YesNo
18769736METHOD FOR OBTAINING SULFATED NANOPARTICLES OF CELLULOSE AND MANNAN FROM ENDOSPERMSJuly 2024March 2025Allow810YesNo
18762939REGIMENS FOR TREATING HIV INFECTIONS AND AIDSJuly 2024October 2024Allow410YesNo
18750829POSITIVE MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4June 2024May 2025Allow1020YesNo
18680557AEROSOL AND TOPICAL ADMINISTRATION OF A FORMULATION CONTAINING CYCLODEXTRIN, QUERCETIN AND ZINC, IN COMBINATION OR SEPARATELY, TO MITIGATE INFECTION BY ENVELOPED VIRUSESMay 2024June 2025Abandon1310NoNo
18676985Method for Prolonging Half-life of Theanine In VivoMay 2024September 2024Allow420NoNo
18672453TRANSITION METAL COMPLEX ASSISTED GREEN HYDROLYSIS FOR NANOCELLULOSE EXTRACTIONMay 2024November 2024Allow610NoNo
18672651Modified Nucleoside PhosphoramiditesMay 2024June 2025Allow1310NoNo
18652718INJECTABLE ANTIBIOTIC FORMULATIONS AND USE THEREOFMay 2024April 2025Allow1110NoNo
18651620METHODS FOR EXTRACTING XYLOSE LIQUID AND CELLULOSE WITH HIGH PURITY FROM CORN STRAWApril 2024January 2025Allow910NoNo
18646035USE OF MARIBAVIR IN TREATMENT REGIMENSApril 2024October 2024Allow610NoNo
18639619TOPICAL COMPOSITIONSApril 2024August 2024Allow410YesNo
18639630TOPICAL COMPOSITIONSApril 2024September 2024Allow510YesNo
18633063COMPOSITIONS OF HYDROXYPROPYL-BETA-CYCLODEXTRIN AND METHODS OF PURIFYING THE SAMEApril 2024September 2024Allow510YesNo
18633087COMPOSITIONS OF HYDROXYPROPYL-BETA-CYCLODEXTRIN AND METHODS OF PURIFYING THE SAMEApril 2024November 2024Allow710YesNo
18630197CONJUGATES COMPRISING CLEAVABLE LINKERSApril 2024October 2024Allow610NoNo
18629820INHIBITORS OF ADENOSINE 5'-NUCLEOTIDASEApril 2024July 2024Allow300NoNo
18609604TREATMENT OF HEARING LOSSMarch 2024October 2024Allow700NoNo
18597197MARIBAVIR ISOMERS, COMPOSITIONS, METHODS OF MAKING AND METHODS OF USINGMarch 2024April 2025Abandon1310NoNo
18594712MARIBAVIR ISOMERS, COMPOSITIONS, METHODS OF MAKING AND METHODS OF USINGMarch 2024April 2025Abandon1310NoNo
18687295PHARMACEUTICAL COMPOSITIONFebruary 2024March 2025Allow1220YesNo
18442204AZITHROMYCIN AND ROXITHROMYCIN DERIVTIVES AS SENOLYTIC DRUGSFebruary 2024September 2024Allow700NoNo
18438664MATERIALS AND METHODS FOR PURIFYING DNA, RNA, AND POLYPEPTIDESFebruary 2024March 2025Abandon1320YesNo
18437424DIARYL TREHALOSE COMPOUNDS AND USES THEREOFFebruary 2024August 2024Allow600NoNo
18435848Process for Preparing ImetelstatFebruary 2024December 2024Allow1010NoNo
18431303SELECTIVE 3-PRENYL 5-METHYL ETHER, 7-O-RHAMNOSIDE FLAVONE FOR THE TREATMENT OF HEPATIC CANCERFebruary 2024September 2024Allow710NoNo
18429102ULTRASOUND-ASSISTED METHOD FOR HIGH-YIELD CELLULOSE EXTRACTION FROM RAW RICE STRAW WITHOUT THE NEED FOR BLEACHING STEPJanuary 2024September 2024Allow810NoNo
18424626PHARMACEUTICAL COMPOSITIONS FOR TREATING OSTEOARTHRITISJanuary 2024March 2025Allow1321YesNo
18420540METHODS OF SELECTIVELY MODULATING GASTROINTESTINAL MICROBIAL GROWTHJanuary 2024April 2025Allow1520YesNo
18417807COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSIONJanuary 2024April 2025Allow1510NoNo
18417312LIQUID COMPOSITION COMPRISING GLUCOSEJanuary 2024August 2024Allow700YesNo
18412414COMPOSITIONS AND METHODS FOR REDUCING MAJOR THROMBOTIC EVENTS IN CANCER PATIENTSJanuary 2024January 2025Allow1210NoNo
18410236COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONSJanuary 2024January 2025Allow1310NoNo
18406942SULFATED OLIGOSACCHARIDES HAVING ANTI-INFLAMMATORY ACTIVITYJanuary 2024April 2025Allow1610YesNo
18403174Sugar Derivatives and Uses Thereof to Prepare Novel Senolytic AgentsJanuary 2024May 2025Abandon1610NoNo
18397012COACERVATE HYALURONAN HYDROGELS FOR DERMAL FILLER APPLICATIONSDecember 2023January 2025Abandon1310YesNo
18573887CHITIN-BASED SUPERABSORBENT MATERIALSDecember 2023September 2024Allow910NoNo
18392583NOVEL POLYMER-COATED CROSSLINKED ALGINATE GEL FIBERDecember 2023February 2025Allow1420YesNo
18391316COMBINATION THERAPY FOR HIV WITH ADENOSINE DERIVATIVE AND CAPSID INHIBITORSDecember 2023January 2025Allow1310NoNo
18390347N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTI-VIRAL USES RELATED THERETODecember 2023January 2025Allow1310NoNo
18534413REAGENTS AND METHODS FOR THE HIGHLY-EFFICIENT SYNTHESIS AND PURIFICATION OF BIOPOLYMERSDecember 2023July 2024Allow810NoNo
18528550Methods And Compositions For Cancer Therapies That Include Delivery Of Halogenated Thymidines And Thymidine Phosphorlylase Inhibitors In Combination With RadiationDecember 2023March 2025Allow1510NoNo
18527321GALACTOPYRANOSYL-CYCLOHEXYL DERIVATIVES AS E-SELECTIN ANTAGONISTSDecember 2023January 2025Abandon1310NoNo
18522850BODY MILKNovember 2023September 2024Allow1020YesNo
18522146COMPOSITIONS AND METHODS FOR PHOSPHORAMIDITE AND OLIGONUCLEOTIDE SYNTHESISNovember 2023April 2025Allow1710NoNo
18522134METHODS AND COMPOSITIONS FOR TREATMENT OF COVID-19November 2023February 2025Abandon1510NoNo
18521467PROCESS FOR EFFICIENT CROSS-LINKING OF HYALURONIC ACIDNovember 2023June 2025Allow1920NoNo
18515359PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOFNovember 2023June 2025Allow1910NoNo
18511231SOLID FORMS OF (2S,3S,4S,5R,6S)-3,4,5-TRIHYDROXY-6-(((4AR,10AR)-7-HYDROXY-1-PROPYL-1,2,3,4,4A,5,10,10A-OCTAHYDROBENZO[G]QUINOLIN-6-YL)OXY)TETRAHYDRO-2H-PYRAN-2-CARBOXYLIC ACIDNovember 2023May 2025Allow1810NoNo
18510757APPLICATION OF CHEBULINIC ACID IN PREPARATION OF ANTI-ROTAVIRUS DRUGSNovember 2023December 2024Abandon1320NoNo
185101286-AZA-NUCLEOSIDE PRODRUGS AS ANTIVIRAL AGENTS FOR TREATING VIRUS INFECTIONSNovember 2023January 2025Abandon1410NoNo
18507662PROCESS FOR THE MANUFACTURE OF (2S,3S,4S,5R,6S)-3,4,5-TRIHYDROXY-6-(((4AR,10AR)-7-HYDROXY-1-PROPYL-1,2,3,4,4A,5,10,10A-OCTAHYDROBENZO[G]QUINOLIN-6-YL)OXY)TETRAHYDRO-2H-PYRAN-2-CARBOXYLIC ACIDNovember 2023April 2025Allow1710NoNo
18506167METHODS OF TREATING DISEASESNovember 2023November 2024Abandon1210NoNo
18505822CORDYCEPIN-BASED DERIVATIZED COMPOUND WITH ANTI-TUMOR EFFECTNovember 2023December 2024Allow1320NoNo
18503499HETEROBIFUNCTIONAL INHIBITORS OF E-SELECTIN AND GALECTIN-3November 2023December 2024Abandon1410NoNo
18504043NUTRITIONAL COMPOSITIONS WITH MFGM AND CERTAIN HUMAN MILK OLIGOSACCHARIDES AND USES THEREOFNovember 2023February 2025Allow1610YesNo
18501779COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN (a) EXPRESSIONNovember 2023August 2024Allow900NoNo
18499248ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOFNovember 2023April 2025Allow1821YesNo
18384643COMPOSITIONS OF HYDROXYPROPYL-BETA-CYCLODEXTRIN AND METHODS OF PURIFYING THE SAMEOctober 2023April 2024Allow510YesNo
18492972PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOFOctober 2023June 2025Allow1910NoNo
18382904COMPOSITION FOR ENHANCING MITOCHONDRIAL FUNCTIONOctober 2023December 2024Allow1411YesNo
18490328Synthesis of Protected 3'-amino Nucleoside MonomersOctober 2023June 2025Abandon2010NoNo
18490238INACTIVATING BACTERIA WITH ELECTRIC PULSES AND ANTIBIOTICSOctober 2023November 2024Allow1310YesNo
18556096USE OF FUNCTIONALISED CHITOSAN IN THE TREATMENT OF INFLAMMATORY/FIBROTIC PATHOLOGIES OF THE RESPIRATORY TRACT AND HEPATIC PATHOLOGIESOctober 2023August 2024Allow910NoNo
18555982USE OF CHONDROITIN SULFATE FOR RELIEVING OCULAR PAINOctober 2023March 2025Allow1720YesNo
18378985PERITONEAL DIALYSIS SOLUTIONOctober 2023October 2024Allow1210NoNo
18377979Nicotinyl Riboside Compounds and Their UsesOctober 2023September 2024Allow1110NoNo
18378097GALNAC COMPOSITIONS FOR IMPROVING SIRNA BIOAVAILABILITYOctober 2023January 2025Allow1520NoNo
18286151NMN AND DERIVATIVES FOR ITS USE IN THE TREATMENT OF DEPRESSION AND/OR ANXIETY IN PATIENTS HAVING A FORM OF PARKINSONISMOctober 2023October 2024Abandon1210YesNo
18480242AMIDE LINKAGES OF SUGAR MOIETIES TO AMINE TERMINATED LEASHES ATTACHED TO CARBOHYDRATE POLYMERSOctober 2023June 2025Allow2021YesNo
18477609TOPICAL COMPOSITIONS DESIGNATED TO MAINTAIN AND/OR RESTORE THE INTEGRITY OF THE MUCOSA AND DAMAGED EPIDERMISSeptember 2023February 2025Allow1610NoNo
18477379METHODS OF SEQUENCING USING NUCLEOTIDES WITH 3' ACETAL BLOCKING GROUPSeptember 2023December 2024Allow1520NoNo
18476119METHODS AND COMPOSITIONS FOR EXTENDING LIFESPANSeptember 2023November 2024Abandon1410NoNo
18472506COMPOUNDS AND METHODS FOR REDUCING MECP2 EXPRESSIONSeptember 2023July 2024Allow1010YesNo
18471764ADMINISTRATION OF NICOTINAMIDE MONONUCLEOTIDE IN THE TREATMENT OF DISEASESeptember 2023August 2024Allow1000NoNo
18370241NOVEL BENZIMIDAZOLE DERIVATIVES, PREPARATION METHOD THEREOF AND USE THEREOF AS ANTI-CANCER AGENT OR ANTI-VIRUS AGENT COMPRISING THE SAMESeptember 2023April 2025Abandon1820NoNo
18467985ADENOSINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAMESeptember 2023November 2024Allow1410NoNo
18244693METHODS FOR THE USE OF 5'-ADENOSINE DIPHOSPHATE RIBOSE (ADPR)September 2023November 2024Allow1510NoNo
18463313METHODS FOR ISOLATING TARGET ANALYTES FROM BIOLOGICAL SAMPLES USING ATPS AND SOLID PHASE MEDIASeptember 2023June 2024Allow1020NoNo
18460637APPLICATION OF HYALURONIC ACID IN PREPARING MEDICINES FOR PREVENTING OR TREATING FERROPTOSIS-RELATED DISEASESSeptember 2023December 2024Allow1640NoNo
18241303COMPOSITIONS COMPRISING AN RNA POLYMERASE INHIBITOR AND CYCLODEXTRIN FOR TREATING VIRAL INFECTIONSSeptember 2023March 2025Abandon1910NoNo
18459507COMPOSITION COMPRISING MANNOSE OLIGOSACCHARIDE AND PROCESS FOR MAKING SAME AND USE THEREOFSeptember 2023June 2025Abandon2110NoNo
18240621OLIGOSACCHARIDE ANALYTICAL STANDARDSAugust 2023July 2024Allow1010NoNo
18237503EFFICIENT AND SCALABLE SYNTHESES OF NICOTINOYL RIBOSIDES AND REDUCED NICOTINOYL RIBOSIDES, MODIFIED DERIVATIVES THEREOF, PHOSPHORYLATED ANALOGS THEREOF, ADENYLYL DINUCLEOTIDE CONJUGATES THEREOF, AND NOVEL CRYSTALLINE FORMS THEREOFAugust 2023October 2024Allow1410YesNo
18237659METHODS AND COMPOSITIONS FOR SUPPORTING HUMAN HEALTH DURING SPACE TRAVELAugust 2023November 2024Abandon1410NoNo
18237228CHITOSAN-DERIVED COMPOSITIONSAugust 2023April 2025Allow2010YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for art-unit 1693.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
25
Examiner Affirmed
11
(44.0%)
Examiner Reversed
14
(56.0%)
Reversal Percentile
95.0%
Higher than average

What This Means

With a 56.0% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.

Strategic Value of Filing an Appeal

Total Appeal Filings
135
Allowed After Appeal Filing
52
(38.5%)
Not Allowed After Appeal Filing
83
(61.5%)
Filing Benefit Percentile
79.2%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 38.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the top 25% across the USPTO, indicating that filing appeals is particularly effective here. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Strategic Recommendations

✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Art Unit 1693 - Prosecution Statistics Summary

Executive Summary

Art Unit 1693 is part of Group 1690 in Technology Center 1600. This art unit has examined 1,740 patent applications in our dataset, with an overall allowance rate of 86.9%. Applications typically reach final disposition in approximately 36 months.

Comparative Analysis

Art Unit 1693's allowance rate of 86.9% places it in the 83% percentile among all USPTO art units. This art unit has a significantly higher allowance rate than most art units at the USPTO.

Prosecution Patterns

Applications in Art Unit 1693 receive an average of 1.92 office actions before reaching final disposition (in the 60% percentile). The median prosecution time is 36 months (in the 16% percentile).

Strategic Considerations

When prosecuting applications in this art unit, consider the following:

  • The art unit's allowance rate suggests a more favorable examination environment compared to the USPTO average.
  • With more office actions than average, plan for relatively streamlined prosecution.
  • The median prosecution time is longer than average and should be factored into your continuation and client communication strategies.
  • Review individual examiner statistics within this art unit to identify examiners with particularly favorable or challenging prosecution patterns.

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.